The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Depressive Disorder, Major

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Depressive Disorder, Major


Psychiatry related information on Depressive Disorder, Major


High impact information on Depressive Disorder, Major


Chemical compound and disease context of Depressive Disorder, Major


Biological context of Depressive Disorder, Major


Anatomical context of Depressive Disorder, Major


Gene context of Depressive Disorder, Major


Analytical, diagnostic and therapeutic context of Depressive Disorder, Major


  1. Blunted adrenocorticotropin but normal beta-endorphin release after human corticotropin-releasing hormone administration in depression. Rupprecht, R., Lesch, K.P., Müller, U., Beck, G., Beckmann, H., Schulte, H.M. J. Clin. Endocrinol. Metab. (1989) [Pubmed]
  2. Association studies in the presence of comorbidity: design and analysis. Wickramaratne, P.J., Hodge, S.E., Rotondo, A. Am. J. Med. Genet. (1998) [Pubmed]
  3. Galanin immunoreactivity in human CSF: studies in eating disorders and Alzheimer's disease. Berrettini, W.H., Kaye, W.H., Sunderland, T., May, C., Gwirtsman, H.E., Mellow, A., Albright, A. Neuropsychobiology (1988) [Pubmed]
  4. Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Brook, D.W., Brook, J.S., Zhang, C., Cohen, P., Whiteman, M. Arch. Gen. Psychiatry (2002) [Pubmed]
  5. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Pettegrew, J.W., Levine, J., McClure, R.J. Mol. Psychiatry (2000) [Pubmed]
  6. Treatment response in depressed patients with enhanced Ca mobilization stimulated by serotonin. Kusumi, I., Suzuki, K., Sasaki, Y., Kameda, K., Koyama, T. Neuropsychopharmacology (2000) [Pubmed]
  7. Corticotropin, cortisol and beta-endorphin responses to the human corticotropin-releasing hormone during melancholia and after unilateral electroconvulsive therapy. Dored, G., Stefansson, S., d'Elia, G., Kågedal, B., Karlberg, E., Ekman, R. Acta psychiatrica Scandinavica. (1990) [Pubmed]
  8. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. Ekselius, L., von Knorring, L. International clinical psychopharmacology. (1998) [Pubmed]
  9. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Witkin, J.M., Tzavara, E.T., Davis, R.J., Li, X., Nomikos, G.G. Trends Pharmacol. Sci. (2005) [Pubmed]
  10. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Hoehn-Saric, R., Ninan, P., Black, D.W., Stahl, S., Greist, J.H., Lydiard, B., McElroy, S., Zajecka, J., Chapman, D., Clary, C., Harrison, W. Arch. Gen. Psychiatry (2000) [Pubmed]
  11. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Yu, Y.W., Tsai, S.J., Chen, T.J., Lin, C.H., Hong, C.J. Mol. Psychiatry (2002) [Pubmed]
  12. Trazodone-induced mania following desipramine-induced mania in major depressive disorders. Arana, G.W., Kaplan, G.B. The American journal of psychiatry. (1985) [Pubmed]
  13. Prolactin changes in major depressive disorders. Asnis, G.M., Nathan, R.S., Halbreich, U., Halpern, F.S., Sachar, E.J. The American journal of psychiatry. (1980) [Pubmed]
  14. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Pacher, P., Ungvari, Z., Kecskemeti, V., Furst, S. Current medicinal chemistry. (1998) [Pubmed]
  15. Depression and anxiety inventories, and the dexamethasone suppression test. Sangal, R., Correa, E.I., DePaulo, J.R. Biol. Psychiatry (1984) [Pubmed]
  16. Stress lymphocytes and the dexamethasone suppression test in major depressive disorders. Miyauchi, K., Hirata-Hibi, M., Hashimoto, M., Hosokawa, K. Biol. Psychiatry (1989) [Pubmed]
  17. Plasma-free and sulfoconjugated MHPG in major depressive disorders: differences between responders to treatment and nonresponders. Mine, K., Okada, M., Mishima, N., Fujiwara, M., Nakagawa, T. Biol. Psychiatry (1993) [Pubmed]
  18. Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Hasler, G., Neumeister, A., van der Veen, J.W., Tumonis, T., Bain, E.E., Shen, J., Drevets, W.C., Charney, D.S. Biol. Psychiatry (2005) [Pubmed]
  19. Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study. Gabbay, V., Hess, D.A., Liu, S., Babb, J.S., Klein, R.G., Gonen, O. Am. J. Psychiatry (2007) [Pubmed]
  20. Regional cerebral blood flow in patients with affective disorders. Delvenne, V., Delecluse, F., Hubain, P.P., Schoutens, A., De Maertelaer, V., Mendlewicz, J. The British journal of psychiatry : the journal of mental science. (1990) [Pubmed]
  21. Specific creatine rise in learned helplessness induced by electroconvulsive shock treatment. Sartorius, A., Vollmayr, B., Neumann-Haefelin, C., Ende, G., Hoehn, M., Henn, F.A. Neuroreport (2003) [Pubmed]
  22. The comparative effects of single and multiple doses of RS-8359, moclobemide and placebo on psychomotor function in healthy subjects. Püchler, K., Schaffler, K., Plenker, A. International clinical psychopharmacology. (1997) [Pubmed]
  23. Increased concentrations of phosphatidylinositol (PI) and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses. Demisch, L., Heinz, K., Gerbaldo, H., Kirsten, R. Prostaglandins Leukot. Essent. Fatty Acids (1992) [Pubmed]
  24. Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression. Zubenko, G.S., Maher, B., Hughes, H.B., Zubenko, W.N., Stiffler, J.S., Kaplan, B.B., Marazita, M.L. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2003) [Pubmed]
  25. Purine and monoamine metabolites in cerebrospinal fluid: parallel purinergic and monoaminergic activation in depressive illness? Niklasson, F., Agren, H., Hällgren, R. J. Neurol. Neurosurg. Psychiatr. (1983) [Pubmed]
  26. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Karishma, K.K., Herbert, J. Eur. J. Neurosci. (2002) [Pubmed]
  27. PHA-stimulated cellular immune function and T-lymphocyte subsets in major depressive disorders. Anesi, A., Franciotta, D., Di Paolo, E., Zardini, E., Melzi d'Eril, G.V., Zerbi, F. Funct. Neurol. (1994) [Pubmed]
  28. The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Renau, T.E. Current opinion in investigational drugs (London, England : 2000) (2004) [Pubmed]
  29. HPA-related CSF neuropeptides in suicide attempters. Träskman-Bendz, L., Ekman, R., Regnéll, G., Ohman, R. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (1992) [Pubmed]
  30. TRH tests with analyses of TSH, prolactin, and GH responses in subtypes of patients with major depressive disorders. Agren, H., Wide, L. Acta psychiatrica Scandinavica. (1986) [Pubmed]
  31. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Shimizu, E., Hashimoto, K., Watanabe, H., Komatsu, N., Okamura, N., Koike, K., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S., Iyo, M. Neurosci. Lett. (2003) [Pubmed]
  32. Growth hormone secretion in prepubertal children with major depression. I. Final report on response to insulin-induced hypoglycemia during a depressive episode. Puig-Antich, J., Novacenko, H., Davies, M., Chambers, W.J., Tabrizi, M.A., Krawiec, V., Ambrosini, P.J., Sachar, E.J. Arch. Gen. Psychiatry (1984) [Pubmed]
  33. Sleep EEG and dexamethasone suppression test findings in outpatients with unipolar major depressive disorders. Rush, A.J., Giles, D.E., Roffwarg, H.P., Parker, C.R. Biol. Psychiatry (1982) [Pubmed]
  34. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Dechant, K.L., Clissold, S.P. Drugs (1991) [Pubmed]
  35. The 'dalhousie serotonin cocktail' for treatment-resistant major depressive disorder. Dursun, S.M., Devarajan, S., Kutcher, S. J. Psychopharmacol. (Oxford) (2001) [Pubmed]
  36. Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behaviour. Löfberg, C., Agren, H., Harro, J., Oreland, L. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. (1998) [Pubmed]
  37. Minaprine and imipramine in the treatment of major depressive disorders. A comparative double-blind study. Bohacek, N., Ravic, M., Bizière, K. Drugs under experimental and clinical research. (1987) [Pubmed]
WikiGenes - Universities